APPLICATION NUMBER:

021064Orig1s011

MEDICAL REVIEW(S)
DIVISION OF MEDICAL IMAGING PRODUCTS

Date: October 21, 2011
Sponsor: Lantheus Medical Imaging
Product: Definity
Regulatory submission: NDA 21064
Reviewer: Ross Filice, M.D. DMIP/ODE IV/CDER
Through: Libero Marzella, M.D. DMIP/ODEIV/CDER

Background
The sponsor originally submitted an efficacy supplement in 2010, new safety information, and new labeling. In July, 2011, the sponsor withdrew a CR letter. A Complete Response letter was issued in June 2011 noting that the safety information was acceptable. The sponsor withdrew and labeling was agreed on that included the new safety information.

However, shortly after the CR letter was issued, the Office of Regulatory Policy found that the sponsor inappropriately bundled their submission and that three separate submissions with three separate user fees should have been submitted. After discussion with the sponsor, they requested that only the safety information be considered with one corresponding user fee.

In accordance with this plan, the sponsor submitted the agreed upon labeling which includes the new safety information. The reviewer recommends approval of the submitted labeling.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROSS W FILICE
10/21/2011

LIBERO L MARZELLA
10/24/2011
## Clinical Review

<table>
<thead>
<tr>
<th>Application Type</th>
<th>sNDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Number(s)</td>
<td>21064</td>
</tr>
<tr>
<td>Priority or Standard</td>
<td>Standard</td>
</tr>
</tbody>
</table>

| Submit Date(s) | 9/29/2010 |
| Received Date(s) | 9/29/2010 |
| PDUFA Goal Date | 7/29/2010 |
| Division / Office | DMIP/ODEIV/OND |

| Reviewer Name(s) | Ross Filice, M.D. |
| Review Completion Date | 9/21/2011 |

**Established Name**: perflutren lipid microsphere injectable suspension  
**(Proposed) Trade Name**: Definity  
**Therapeutic Class**: Diagnostic Agent  
**Applicant**: Lantheus Medical Imaging, Inc.  
**Formulation(s)**: perflutren microspheres and octafluoropropane (after Vialmix activation)  
**Dosing Regimen**: **Bolus**: 10μL/kg within 30-60 seconds followed by 10mL saline flush. If necessary, but only after at least 30 minutes have elapsed, second 10μL/kg
dose and saline flush to prolong enhancement.

**Infusion**: 1.3mL in 50mL saline initiated at 4.0 mL/min with titration to optimize enhancement, not to exceed 10mL/min

**Imaging**: Mechanical index of ultrasound device should be 0.8 or less. Enhanced images should be evaluated in combination with non-contrast images.

**Indication(s)** Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

**Intended Population(s)** Patients with suboptimal echocardiograms.
# Table of Contents

1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ............................................. 11
   1.1 Recommendation on Regulatory Action ....................................................... 11
   1.2 Risk Benefit Assessment ............................................................................ 11
   1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies 13
   1.4 Recommendations for Postmarket Requirements and Commitments .......... 13

2 INTRODUCTION AND REGULATORY BACKGROUND ................................... 13
   2.1 Product Information .................................................................................. 13
   2.2 Currently Available Treatments for Proposed Indications .......................... 14
   2.3 Availability of Proposed Active Ingredient in the United States ............... 15
   2.4 Important Safety Issues and Regulatory History ..................................... 15
   2.5 Other Relevant Background Information ............................................... 18

3 ETHICS AND GOOD CLINICAL PRACTICES ................................................. 18
   3.1 Submission Quality and Integrity ............................................................... 18
   3.2 Compliance with Good Clinical Practices ............................................... 18
   3.3 Financial Disclosures .............................................................................. 19

4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW
   DISCIPLINES ........................................................................................................ 19
   4.1 Chemistry Manufacturing and Controls ................................................... 19
   4.2 Clinical Microbiology ............................................................................... 19
   4.3 Preclinical Pharmacology/Toxicology ..................................................... 19
   4.4 Clinical Pharmacology ............................................................................ 19
   4.4.1 Mechanism of Action ....................................................................... 19
   4.4.2 Pharmacodynamics ........................................................................ 19
   4.4.3 Pharmacokinetics .......................................................................... 19

5 SOURCES OF CLINICAL DATA ..................................................................... 20
   5.1 Tables of Studies/Clinical Trials ............................................................... 20
   5.2 Review Strategy ...................................................................................... 20
   5.3 Discussion of Individual Studies/Clinical Trials ....................................... 21
   5.3.1 Efficacy ......................................................................................... 21
   5.3.2 Safety ............................................................................................. 21

6 REVIEW OF EFFICACY ............................................................................... 22
   Efficacy Summary .......................................................................................... 22
   6.1 Indication ............................................................................................... 22
   6.1.1 Methods ......................................................................................... 23
   6.1.2 Demographics ................................................................................. 28
   6.1.3 Subject and Image Disposition ......................................................... 30
   6.1.4 Analysis of Primary Endpoint(s) ...................................................... 32
   6.1.5 Analysis of Secondary Endpoints(s) ............................................... 38
   6.1.7 Subpopulations ................................................................................ 42
6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations .... 42
6.1.9 Discussion of Persistence of Efficacy and/or Tolerance Effects ............ 43
6.1.10 Additional Efficacy Issues/Analyses .................................................. 43

7 REVIEW OF SAFETY .................................................................................. 44

Safety Summary ............................................................................................. 44
7.1 Methods .................................................................................................... 44
7.1.1 Studies/Clinical Trials Used to Evaluate Safety ....................................... 45
7.1.2 Categorization of Adverse Events .......................................................... 45
7.1.3 Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence ........................................................................................................ 46

7.2 Adequacy of Safety Assessments .............................................................. 46
7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations ........................................................................................................ 46
7.2.2 Explorations for Dose Response ................................................................ 53
7.2.3 Special Animal and/or In Vitro Testing .................................................... 53
7.2.4 Routine Clinical Testing .......................................................................... 53
7.2.5 Metabolic, Clearance, and Interaction Workup .......................................... 53
7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class .. 53

7.3 Major Safety Results .................................................................................. 54
7.3.1 Deaths .................................................................................................... 54
7.3.2 Nonfatal Serious Adverse Events ............................................................ 56
7.3.3 Dropouts and/or Discontinuations ........................................................... 58
7.3.4 Significant Adverse Events ...................................................................... 59

7.4 Supportive Safety Results .......................................................................... 61
7.4.1 Common Adverse Events ........................................................................ 61
7.4.2 Laboratory Findings ................................................................................ 64
7.4.3 Vital Signs ............................................................................................... 65
7.4.4 Electrocardiograms (ECGs) ..................................................................... 71
7.4.5 Special Safety Studies/Clinical Trials ....................................................... 72
7.4.6 Immunogenicity ....................................................................................... 72

7.5 Other Safety Explorations .......................................................................... 73
7.5.1 Dose Dependency for Adverse Events .................................................... 73
7.5.2 Time Dependency for Adverse Events .................................................... 73
7.5.3 Drug-Demographic Interactions ............................................................... 73
7.5.4 Drug-Disease Interactions ...................................................................... 74
7.5.5 Drug-Drug Interactions .......................................................................... 74

7.6 Additional Safety Evaluations .................................................................... 74
7.6.1 Human Carcinogenicity ......................................................................... 74
7.6.2 Human Reproduction and Pregnancy Data ............................................. 74
7.6.3 (b) (4) ..................................................................................................... 74
7.6.4 Other Subgroup Analyses ....................................................................... 76
7.6.5 Overdose, Drug Abuse Potential, Withdrawal and Rebound .................. 76

7.7 Additional Submissions / Safety Issues ...................................................... 76

8 POSTMARKET EXPERIENCE .................................................................... 77
DEFINITY (perflutren lipid microsphere) injectable suspension

8.1 Deaths

8.2 Adverse Events

8.3 Utilization

9 APPENDICES

9.1 Literature Review/References

9.2 Labeling Recommendations

9.3 Advisory Committee Meeting
### Table of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Physical Characteristics of Definity</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>Physical Characteristics of Optison</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>Currently Approved Ultrasound Contrast Agents</td>
<td>14</td>
</tr>
<tr>
<td>4</td>
<td>Studies submitted in the sNDA</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>Studies Used To Evaluate Efficacy</td>
<td>23</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>28</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>29</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>29</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>29</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>37</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>41</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>16</td>
<td>Studies Used to Evaluate Safety</td>
<td>45</td>
</tr>
<tr>
<td>17</td>
<td>DMP 115-415 - Demographics</td>
<td>47</td>
</tr>
<tr>
<td>18</td>
<td>DMP 115-416 - Demographics</td>
<td>48</td>
</tr>
<tr>
<td>19</td>
<td>DMP 115-418 - Demographics</td>
<td>48</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>49</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>50</td>
</tr>
<tr>
<td>22</td>
<td></td>
<td>50</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>51</td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>25</td>
<td></td>
<td>53</td>
</tr>
<tr>
<td>26</td>
<td>DMP 115-418 - Mortality in All Patients</td>
<td>54</td>
</tr>
<tr>
<td>27</td>
<td>DMP 115-418 - Mortality in Matched Datasets</td>
<td>54</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>55</td>
</tr>
<tr>
<td>29</td>
<td></td>
<td>56</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td>57</td>
</tr>
<tr>
<td>31</td>
<td></td>
<td>57</td>
</tr>
<tr>
<td>32</td>
<td></td>
<td>58</td>
</tr>
<tr>
<td>33</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>34</td>
<td>DMP 115-415 - Most Common Adverse Events</td>
<td>62</td>
</tr>
<tr>
<td>35</td>
<td>DMP 115-416 - Most Common Adverse Events</td>
<td>62</td>
</tr>
<tr>
<td>36</td>
<td></td>
<td>63</td>
</tr>
<tr>
<td>37</td>
<td></td>
<td>63</td>
</tr>
<tr>
<td>38</td>
<td></td>
<td>64</td>
</tr>
<tr>
<td>39</td>
<td>DMP 115-415 - ECG Changes</td>
<td>71</td>
</tr>
<tr>
<td>40</td>
<td>Time Dependency of Adverse Events</td>
<td>73</td>
</tr>
<tr>
<td>41</td>
<td>DMP 115-415 - Subgroup Adverse Event Rate</td>
<td>73</td>
</tr>
<tr>
<td>42</td>
<td>Definity - Example Postmarketing Fatal Adverse Event Reports</td>
<td>77</td>
</tr>
</tbody>
</table>
Table of Figures

Figure 1: Definity Boxed Warning from 2007 ................................................................. 16
Figure 2: Definity Contraindications in 2007 ................................................................. 16
Figure 3: Modifications to the Black Box Warning in 2008 ........................................... 17
Figure 4: ........................................................................................................................... 24
Figure 5: ........................................................................................................................... 25
Figure 6: ........................................................................................................................... 25
Figure 7: ........................................................................................................................... 26
Figure 8: ........................................................................................................................... 27
Figure 9: ........................................................................................................................... 31
Figure 10: ......................................................................................................................... 32
Figure 11: ......................................................................................................................... 33
Figure 12: ......................................................................................................................... 34
Figure 13: ......................................................................................................................... 35
Figure 14: ......................................................................................................................... 36
Figure 15: ......................................................................................................................... 37
Figure 16: ......................................................................................................................... 37
Figure 17: ......................................................................................................................... 38
Figure 18: ......................................................................................................................... 39
Figure 19: ......................................................................................................................... 40
Figure 20: DMP 115-415 - Adverse Events ................................................................. 61
Figure 21: DMP 115-415 - Heart Rate Over Time ..................................................... 65
Figure 22: DMP 115-416 - Mean Systolic Pulmonary Arterial Pressure Over Time ... 66
Figure 23: ......................................................................................................................... 66
Figure 24: ......................................................................................................................... 67
Figure 25: ......................................................................................................................... 68
Figure 26: ......................................................................................................................... 69
Figure 27: ......................................................................................................................... 69
Figure 28: ......................................................................................................................... 70
Figure 29: ......................................................................................................................... 70
Trials ................................................................................................................................. 70
Figure 30: DMP 115-416 - Mean Immunology Parameters ....................................... 72
Figure 31: ......................................................................................................................... 75
Figure 32: ......................................................................................................................... 75
Figure 33: ......................................................................................................................... 76
Figure 34: Sales Data and Projected Patient Utilization ............................................ 79
**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>µm</td>
<td>micrometer</td>
</tr>
<tr>
<td>A2C</td>
<td>apical 2 chamber view</td>
</tr>
<tr>
<td>A4C</td>
<td>apical 4 chamber view</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AERS</td>
<td>Adverse Event Reporting System</td>
</tr>
<tr>
<td>AHRQ</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>AVI</td>
<td>audio video interleave</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BPM</td>
<td>beats per minute</td>
</tr>
<tr>
<td>C3a</td>
<td>complement protein C3a</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CDM</td>
<td>common data model</td>
</tr>
<tr>
<td>DSE</td>
<td>dobutamine stress echocardiography</td>
</tr>
<tr>
<td>EBD</td>
<td>Endocardial border delineation</td>
</tr>
<tr>
<td>EBL</td>
<td>Endocardial border length</td>
</tr>
<tr>
<td>EBLc</td>
<td>Endocardial border length (continuous)</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ED</td>
<td>emergency department</td>
</tr>
<tr>
<td>EE</td>
<td>Efficacy-evaluable population</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FDAAA</td>
<td>Food and Drug Administration Amendments Act</td>
</tr>
<tr>
<td>GE</td>
<td>General Electric (Healthcare)</td>
</tr>
<tr>
<td>HCUP</td>
<td>Healthcare Cost and Utilization Project (AHRQ)</td>
</tr>
<tr>
<td>htn</td>
<td>hypertension</td>
</tr>
<tr>
<td>ICL</td>
<td>imaging core laboratory</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>IHCarUS</td>
<td>Inpatient Health Care Utilization System (SDI)</td>
</tr>
<tr>
<td>LAD</td>
<td>left anterior descending (coronary artery)</td>
</tr>
<tr>
<td>LMI</td>
<td>Lantheus Medical Imaging</td>
</tr>
<tr>
<td>LVO</td>
<td>Left ventricular opacification</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters of mercury</td>
</tr>
<tr>
<td>MPI</td>
<td>myocardial perfusion imaging</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>NHDS</td>
<td>National Hospital Discharge Survey</td>
</tr>
<tr>
<td>NOS</td>
<td>not otherwise specified</td>
</tr>
<tr>
<td>PASP</td>
<td>pulmonary arterial systolic pressure</td>
</tr>
<tr>
<td>PHI</td>
<td>protected health information</td>
</tr>
<tr>
<td>PLR</td>
<td>Physician Labeling Rule</td>
</tr>
<tr>
<td>PMC</td>
<td>Postmarketing Commitment</td>
</tr>
<tr>
<td>PMR</td>
<td>Postmarketing Requirement</td>
</tr>
<tr>
<td>PR</td>
<td>PR interval</td>
</tr>
<tr>
<td>PP</td>
<td>Per-protocol population</td>
</tr>
<tr>
<td>PS</td>
<td>primary suspect</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>pulm</td>
<td>pulmonary</td>
</tr>
<tr>
<td>PVC</td>
<td>premature ventricular complex</td>
</tr>
<tr>
<td>QA</td>
<td>quality analysis</td>
</tr>
<tr>
<td>QRS</td>
<td>QRS interval</td>
</tr>
<tr>
<td>QT</td>
<td>QT interval</td>
</tr>
<tr>
<td>QTc</td>
<td>QT interval, corrected</td>
</tr>
<tr>
<td>REMS</td>
<td>Risk Evaluation and Mitigation Strategies</td>
</tr>
<tr>
<td>RR</td>
<td>RR interval</td>
</tr>
<tr>
<td>RTCE</td>
<td>real-time contrast echocardiography</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAF</td>
<td>Safety-evaluable population</td>
</tr>
<tr>
<td>SDI</td>
<td>SDI Health, LLC</td>
</tr>
<tr>
<td>SS</td>
<td>secondary suspect</td>
</tr>
<tr>
<td>TEAE</td>
<td>treatment emergent adverse event</td>
</tr>
<tr>
<td>U.S.</td>
<td>United States</td>
</tr>
<tr>
<td>VA</td>
<td>U.S. Department of Veterans Affairs</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>VHS</td>
<td>video home system</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cells</td>
</tr>
</tbody>
</table>
1 Recommendations/Risk Benefit Assessment

1.1 Recommendation on Regulatory Action

The clinical reviewer recommends a complete response (CR) regulatory action for this labeling supplement because of failed negotiations with the Sponsor to produce an acceptable revised package insert for Definity.

With regard to safety, the reviewer has determined that the sponsor has provided important new data from a registry study and a pulmonary hemodynamic study. The reviewer does not find the submitted retrospective observational study data to be persuasive. The reviewer does not agree with the sponsor’s proposal to drastically alter the warnings in the package insert including removal of the boxed warning. However, the reviewer recommends modification of the boxed warning and updating other safety information to reflect current understanding.

1.2 Risk Benefit Assessment

The risk-benefit profile of Definity remains favorable. Definity provides important additional structural delineation, and thus important information about the heart, in the appropriate clinical setting. This information can be crucial in clinical care. Serious cardiopulmonary and anaphylactoid events are observed in association with Definity administration, but are uncommon. Causality is not always clear as the patients who receive Definity commonly have serious underlying cardiac comorbidities, may be receiving multiple concomitant medications, and may receive Definity in the off-label setting of stress echocardiography.

Overall, the submitted safety and postmarketing data suggest that the serious adverse reaction rate for Definity is reasonably low. While there are limitations with many of the data sources, and while there is significant uncertainty when estimating event rates from data such as spontaneous postmarketing reports, the present data are consistent with an estimated serious event rate between 1:100-1:1000.

However, serious cardiopulmonary events and fatalities are still observed, even after labeling changes made in 2007 and 2008. It is difficult to clearly establish causality, particularly in the patient population and setting in which Definity is commonly administered, but there is evidence that Definity has at least a partial contributory role. Many of these events occur within 30 minutes of administration, underscoring the
importance of proper warning, patient observation, and the availability of life-supporting equipment and trained personnel.

Given the persistence of these events, the reviewer recommends keeping the boxed warning in the Definity label. However, some label modifications are necessary to better reflect our current understanding of the clinical picture. The reviewer recommends better describing our understanding of the incidence of serious reactions by using the word “uncommon” in the description of the serious events. The submitted safety data supports removing the specific pulse oximetry and ECG monitoring requirements. We continue to recommend observation of all patients as many of the serious events occur within 30 minutes.

It should be noted that the sponsor has not requested a new indication, but has proposed removing the statement:

\[\text{The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.}\]

from the Indications and Usage section. This statement was added in 2007 because of lack of data on the safety of Definity in clinical use. The results of the registry study and the pulmonary hemodynamic study support removing this statement from the label.
We also recommend updating the Warnings and Precautions section and the Adverse Reactions section to reflect our current understanding. The two most robust postmarketing studies, the safety registry and pulmonary hemodynamic studies, should be included in the Clinical Trials section. The entire label should be converted to Physician Labeling Rule format.

1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies

Continued postmarketing reporting and pharmacovigilance of cardiopulmonary reactions. However, no Risk Evaluation and Mitigation Strategies (REMS) are necessary.

1.4 Recommendations for Postmarket Requirements and Commitments

None.

2 Introduction and Regulatory Background

2.1 Product Information

DEFINITY (perflutren lipid microsphere) injectable suspension is an intravenous ultrasound contrast agent originally approved for marketing in the United States in 2001. Definity has the following Indications and Usage statement:

*Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.*

*The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.*

Definity is supplied in a vial containing perflutren and a blend of several different lipids. Prior to usage, the mixture is activated using a proprietary activation device, which results in perflutren lipid microsphere formation. The mean diameter of the microspheres ranges from 1.1μm-3.3μm with a maximum diameter of 20μm and with 98% of the microspheres having a diameter of less than 10μm (Table 1).
Table 1: Physical Characteristics of Definity

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Diameter (µm)</td>
<td>1.1-3.3</td>
</tr>
<tr>
<td>Maximum Diameter (µm)</td>
<td>20</td>
</tr>
<tr>
<td>% less than 10µm</td>
<td>98%</td>
</tr>
</tbody>
</table>

By encapsulating a gas in numerous tiny lipid or protein shells, Definity provides contrast to the adjacent blood when injected intravenously and viewed by ultrasound. Definity uses perflutren gas, also called octafluoropropane, for this purpose.

Optison (perflutren protein-type A microspheres) is the only other ultrasound contrast agent currently approved in the United States. The basic structure of Optison is similar to Definity in that it is comprised of many small lipid microspheres which contain echogenic gas. The lipid shell in Optison is composed of human serum albumin and contains the same gas as is used in Definity, namely perflutren. The microspheres in Optison are somewhat larger than in Definity (Table 2).

Table 2: Physical Characteristics of Optison

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Diameter (µm)</td>
<td>3.3-4.5</td>
</tr>
<tr>
<td>Maximum Diameter (µm)</td>
<td>32</td>
</tr>
<tr>
<td>% less than 10µm</td>
<td>95%</td>
</tr>
</tbody>
</table>

Echocardiograms are used to image the heart and diagnose cardiovascular diseases in a wide range of age groups, populations, and conditions. In some patients, echocardiograms without contrast do not delineate all structures of the heart and are considered suboptimal. In this setting, addition of a contrast agent such as Definity has been shown to improve the structural delineation of certain parts of the left ventricular chamber. No ultrasound contrast agent, including Definity, has an indication to evaluate physiology or detect disease.

Because there are a small number of microspheres that are greater than 10µm in diameter (slightly larger than a red blood cell), it is thought that these largest microspheres embolize in the pulmonary vasculature after injection. The majority of the microspheres, which are smaller than a red blood cell, pass through the pulmonary vasculature and can be imaged in the left ventricle or elsewhere in the systemic circulation.

2.2 Currently Available Treatments for Proposed Indications

Two ultrasound contrast agents are currently approved in the United States (Table 3).

Table 3: Currently Approved Ultrasound Contrast Agents

<table>
<thead>
<tr>
<th>Contrast Agent</th>
<th>NDA</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definity (perflutren lipid microspheres)</td>
<td>21064</td>
<td>7/31/2001</td>
</tr>
<tr>
<td>Optison (perflutren protein-type A microspheres)</td>
<td>20899</td>
<td>12/31/1997</td>
</tr>
</tbody>
</table>

Optison has the same indication statement as Definity.
OPTISON is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.

The safety and efficacy of OPTISON with exercise stress or pharmacologic stress testing have not been established.

2.3 Availability of Proposed Active Ingredient in the United States

No known availability issues of the active ingredient.

2.4 Important Safety Issues and Regulatory History

Initial Approval

Because both of the existing approved ultrasound agents contain numerous small microspheres, there have been concerns related to microvascular obstruction since initial approval.

Contraindications have always included intra-arterial administration and administration in patients with known right-to-left cardiac shunts because of these concerns. Nonclinical studies showed that intravenous administration did not result in significant systemic microvascular obstruction, presumably because of filtering of the largest microspheres by the pulmonary vasculature.

The initial Warnings section also recommended caution in patients with chronic pulmonary vascular disorders because of these concerns, though initial nonclinical and clinical data did not show evidence of pulmonary compromise. The Precautions section also included a statement that the safety of microspheres in mechanical ventilation had not been studied.

It was also known at the time of initial approval that certain ultrasound techniques, specifically imaging with high mechanical index values, could cause microsphere cavitation and potentially lead to ventricular arrhythmias. This concern was reflected in the Precautions section of the original label.

A number of serious adverse events and deaths had been reported in clinical trials using Definity, but at the time it was felt that these were likely attributable to underlying cardiopulmonary conditions.

2006-2007

In 2006 and 2007, FDA became aware of a number of additional deaths temporally related to the administration of ultrasound contrast agents. These deaths generally followed cardiovascular collapse or a hypersensitivity reaction and occurred
Division of Medical Imaging Products - Clinical Review
Ross Filice, M.D.
NDA 21064
DEFINITY (perflutren lipid microsphere) injectable suspension

predominantly in patients with underlying cardiac or pulmonary disease. Additionally, nonclinical studies reported significant pulmonary and systemic hemodynamic changes after administration of ultrasound contrast agents, particularly in the pig.

Because of these findings, a number of modifications were made to both the Definity and Optison labels in 2007 including addition of boxed warnings and new contraindications (Figures 1-2). FDA also required the sponsors to perform postmarketing clinical studies to further characterize the risks involved.

**Figure 1: Definity Boxed Warning from 2007**

WARNING: Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred during or within 30 minutes following DEFINITY® administration.

- Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
- Monitor patients during and for 30 minutes following DEFINITY® administration, including vital sign measurements and electrocardiography in all patients and cutaneous oxygen saturation in patients at risk for hypoxemia. Always have resuscitation equipment and trained personnel readily available (see WARNINGS).

**Figure 2: Definity Contraindications in 2007**

Do not administer DEFINITY® to patients with known or suspected:

- Right-to-left, bi-directional, or transient right-to-left cardiac shunts,
- Worsening or clinically unstable congestive heart failure,
- Acute myocardial infarction or acute coronary syndromes,
- Serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of the QT interval,
- Respiratory failure, as manifest by signs or symptoms of carbon dioxide retention or hypoxemia,
- Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature,
- Hypersensitivity to perflutren (see WARNINGS).

Do not administer DEFINITY® by intra-arterial injection.

The Warnings section was also revised to include the following subheadings with associated descriptions:

- Serious Cardiopulmonary Reactions,
- Anaphylactoid Reactions
- Systemic Embolization of Definity® in Patients with Cardiac Shunts
- High Ultrasound Mechanical Index
2008

Shortly after these major label revisions, the echocardiography community expressed concern that the restrictive nature of the new labeling would preclude the use of ultrasound contrast agents, especially in critically ill patients who they argued needed these agents most, and would therefore result in patient harm. Additionally, two new published reports were reviewed which suggested that the concerning nonclinical pulmonary hemodynamic changes may not translate to humans (Erb et al., 2001; Soman et al., 2000).

With this updated information, the boxed warning was revised to focus more specifically on those populations felt to be most at risk (Figure 3).

**Figure 3: Modifications to the Black Box Warning in 2008**

**WARNING: Serious Cardiopulmonary Reactions**

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perfluoron-containing microsphere administration.

- Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINdicATIONS).
- In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation patients during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
- Always have resuscitation equipment and trained personnel readily available.

In addition, the Contraindications section was substantively reverted to its original form, namely cardiac shunts, hypersensitivity to perfluoron, and intra-arterial injection.

**Advisory Committee**

In addition to these labeling changes, the FDA instituted two postmarketing requirement (PMR) studies to further characterize the safety of Definity:

- A study that will utilize an existing database to compare in hospital mortality in critically ill patients undergoing echocardiography with and without the sponsor’s ultrasound contrast agent.
- A clinical trial that, at a minimum, provides pulmonary hemodynamic data from at least 30 patients with known or suspected cardiac disease who are undergoing an echocardiogram with the sponsor’s ultrasound contrast agent.
Division of Medical Imaging Products - Clinical Review
Ross Filice, M.D.
NDA 21064
DEFINITY (perflutren lipid microsphere) injectable suspension

A third voluntary postmarketing commitment was also performed:

- A study of at least 1000 patients undergoing echocardiography with the sponsor's ultrasound contrast agent in routine clinical practice.

On June 24, 2008, the Cardiovascular and Renal Drugs Advisory Committee met to discuss the safety issues and new information related to ultrasound contrast agents. The Committee generally agreed with the assessments made by the FDA and endorsed the proposed risk assessment plans.

2008 - Present

Over the next few years, these postmarketing studies were completed and submitted to the FDA. An Advisory Committee was again convened on May 2, 2011 to discuss the results of these studies as well as interval postmarketing reports for the two ultrasound contrast agents approved in the United States (Definity and Optison) as well as an investigational agent that is approved and widely used in Europe and Asia (SonoVue). Lantheus Medical Imaging also submitted the supplementary NDA under review which included the results of these postmarketing studies with additional material to support both efficacy and safety changes.

2.5 Other Relevant Background Information

The ultrasound contrast agents have generally been considered as a class with similar mechanism of action and similar adverse event profiles. Similar findings and adverse events as those discussed above have been observed with Optison, currently the only other FDA approved ultrasound contrast agent. Because of this, virtually identical safety labeling changes were made for Optison along with Definity.

Several other investigational ultrasound contrast agents also exist, the most prominent in the U.S. being SonoVue, which is currently marketed in many foreign countries. A similar adverse event profile has been seen with SonoVue in both clinical trial and foreign postmarketing experience.

3 Ethics and Good Clinical Practices

3.1 Submission Quality and Integrity

Data quality and integrity are acceptable. Site inspections were not performed by the Agency as this is a supplemental application.

3.2 Compliance with Good Clinical Practices

A statement of Good Clinical Practice was submitted for DMP 115-415, DMP 115-416, and DMP 115-501 including all of the individual trials that comprised DMP 115-501.
The final study report for DMP 115-419 states that the study was conducted in conformance with all applicable country and local requirements regarding ethical committee review and informed consent. The remaining data are retrospective reviews, literature reviews, or postmarketing safety reports.

### 3.3 Financial Disclosures

A Financial Certification and Disclosure form was submitted. Several investigators in DMP 115-415 have received speakers honoraria totaling greater than $25,000, but there does not appear to be substantial conflict of interest.

### 4 Significant Efficacy/Safety Issues Related to Other Review Disciplines

#### 4.1 Chemistry Manufacturing and Controls

No additional data are needed, nor were any new data submitted.

#### 4.2 Clinical Microbiology

No additional data are needed, nor were any new data submitted.

#### 4.3 Preclinical Pharmacology/Toxicology

No additional data are needed, nor were any new data submitted.

#### 4.4 Clinical Pharmacology

No additional data are needed, nor were any new data submitted.

##### 4.4.1 Mechanism of Action

No additional data are needed, nor were any new data submitted.

##### 4.4.2 Pharmacodynamics

No additional data are needed, nor were any new data submitted.

##### 4.4.3 Pharmacokinetics

No additional data are needed, nor were any new data submitted.
5 Sources of Clinical Data

5.1 Tables of Studies/Clinical Trials

Nine reports were submitted for review. Four of these are studies in the setting of rest echocardiography and are focused on safety. (Table 4).

<table>
<thead>
<tr>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMP 115-415</td>
<td>Open-label, nonrandomized, post-marketing registry focused on safety. 1053 patients were enrolled who received echocardiograms with Definity in typical clinical practice.</td>
</tr>
<tr>
<td>DMP 115-416</td>
<td>Open-label, nonrandomized, multicenter study of pulmonary hemodynamics in 32 patients with and without pulmonary hypertension.</td>
</tr>
<tr>
<td>DMP 115-418</td>
<td>Retrospective, observational database review of mortality in critically ill patients who received echocardiograms. Patients who received echocardiograms with Definity were matched to patients who received noncontrast echocardiograms using propensity score matching techniques.</td>
</tr>
</tbody>
</table>

* These studies were post-marketing commitments or requirements that were established as part of a risk assessment plan along with the labeling changes in 2007-2008.

5.2 Review Strategy

The reviewer focused on the assessment of safety and efficacy primarily in the indicated population and secondarily in the broader clinical use population. The studies in the setting of rest echocardiography focused on safety and these were evaluated both
5.3 Discussion of Individual Studies/Clinical Trials

5.3.1 Efficacy

The individual protocols and study reports for each of the 5 included trials were also reviewed. Raw data from the submission was analyzed to confirm the sponsor's analyses as well as to perform original analyses to help clarify areas of ambiguity and to perform exploratory analyses.

5.3.2 Safety

Four safety studies were performed in the setting of rest echocardiography. Two of these were post-marketing requirements established as part of a risk assessment plan established in 2007 because of concerning spontaneous postmarketing reports and other findings. A third was a post-marketing commitment established shortly after initial approval that was included as part of the risk assessment plan.

DMP 115-418 was a post-marketing requirement established because of a lack of safety data in the critically ill population. This trial was a retrospective, observational database review of a large number of patients using propensity score matching techniques.

DMP 115-416 was a post-marketing requirement because of concerning pulmonary hemodynamic findings in pigs. This study focused on pulmonary hemodynamic changes after Definity administration in a small group of subjects with pulmonary hypertension. Adverse events, vital signs, ECGs, and laboratory measurements were also evaluated.
DMP 115-415 was a post-marketing commitment which was a prospective safety registry of 1053 patients who underwent echocardiograms with Definity in routine clinical practice. Adverse events, vital signs, and ECG data was recorded.

6 Review of Efficacy

Efficacy Summary

6.1 Indication

The original indication for Definity from 2001 is as follows:

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

In 2007, an additional statement was added immediately after the indication which reflected concerns about lack of safety data in the setting of stress echocardiography with Definity and which read:
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

The sponsor has not proposed to add a new indication in the setting of stress, rather they have proposed removing the additional statement described above that was added in 2007.

In addition, they propose including data from their postmarketing commitment and requirements.

6.1.1 Methods
7 Review of Safety

Safety Summary

Safety data has been submitted from a wide variety of sources.

Three studies, in the setting of rest echocardiography, were postmarketing commitments and requirements that were performed in conjunction with an FDA safety plan after the labeling changes in 2007-2008. The results of these three studies were presented at an FDA Advisory Committee meeting on May 2, 2011. While these studies have important limitations, particularly the retrospective database review, there is reasonable assurance that the serious adverse reaction rate with Definity is low, even in a patient population that is less stable and affected by more complicating factors than the narrow population evaluated in the premarket studies.

7.1 Methods

Seven reports of safety data are submitted, four for Definity echocardiography at rest.
## 7.1.1 Studies/Clinical Trials Used to Evaluate Safety

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>* DMP 115-415</td>
<td>Open-label, nonrandomized, post-marketing registry focused on safety. 1053 patients were enrolled who received echocardiograms with Definity in typical clinical practice.</td>
</tr>
<tr>
<td>* DMP 115-416</td>
<td>Open-label, nonrandomized, multicenter study of pulmonary hemodynamics in 32 patients with and without pulmonary hypertension.</td>
</tr>
<tr>
<td>* DMP 115-418</td>
<td>Retrospective, observational database review of mortality in critically ill patients who received echocardiograms. Patients who received echocardiograms with Definity were matched to patients who received noncontrast echocardiograms using propensity score matching techniques.</td>
</tr>
</tbody>
</table>

* These trials were post-marketing commitments or requirements that were established as part of a risk assessment plan along with the labeling changes in 2007-2008.

## 7.1.2 Categorization of Adverse Events

The Integrated Summary of Safety provides a description of how adverse events (AE), treatment emergent adverse events (TEAE), and serious adverse events (SAE) are categorized.

All adverse events, including observed and patient volunteered events, were recorded as adverse events regardless of the assessment of causality. An adverse event was considered treatment emergent if:

- it appeared for the first time on or after the first dose of the study drug
- it represented an exacerbation of a condition observed pretreatment

Serious adverse events were defined as any event that met any of the following criteria:

- resulted in death
- was life threatening at the time of the event
- required in-patient hospitalization or prolongation of an existing hospitalization
DEFINITY (perflutren lipid microsphere) injectable suspension

- resulted in persistent or significant disability/incapacity defined as a substantial disruption of a person’s ability to conduct normal life functions
- was a congenital anomaly/birth defect
- was an important medical event that, when based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed above

7.1.3 Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence

7.2 Adequacy of Safety Assessments

7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations

Approximately 80,000 patients were exposed to at least one dose of Definity in the seven trials focused on safety. Most patients were adults with mean ages ranging from 56-66

Some patients were exposed in the setting of rest echocardiography and some in stress. Dosing schemes were variable across these trials and were absent in two trials. Many of the patients received more than the label recommended dose.

Nearly 2 million patients who underwent noncontrast echocardiograms were included in these trials using various methodologies. These largely come from DMP 115-418, the retrospective database review. Mean ages for these patients ranged from 56-67.

DMP 115-415
All patients in this trial received single or multiple bolus dosing of Definity.

In rest, 1018 patients received a mean dose of 0.475 mL (range 0.05-2 mL) corresponding with a mean weight based dosing of 5.15 microL/kg (range 0.42-23 microL/kg) with 32 patients receiving one bolus dose higher than the labeled recommendation and one additional patient receiving multiple boluses with a total dose higher than the labeled recommendation. Three patients did not have reported dose information in rest.

In stress, 452 patients received a mean dose of 0.499 mL (range 0.09-2.1 mL) corresponding with a mean weight based dosing of 5.32 microL/kg (range 0.67-30.9 microL/kg) with 15 patients receiving one bolus dose higher than the labeled
recommendation and two additional patients receiving multiple boluses with a total dose higher than the labeled recommendation. Two patients did not have reported dose information in stress.

Slightly more patients in this trial were under 65 years of age. More patients were male than female. The majority of patients were white (Table 17).

Table 17: DMP 115-415 - Demographics

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Mean ± SD</th>
<th>61.3 ± 12.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;65</td>
<td></td>
<td>57.8%</td>
</tr>
<tr>
<td>≥65</td>
<td></td>
<td>42.2%</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>62.0%</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>38.0%</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>81.5%</td>
</tr>
<tr>
<td>Asian</td>
<td></td>
<td>1.2%</td>
</tr>
<tr>
<td>African American</td>
<td></td>
<td>14.3%</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>2.4%</td>
</tr>
</tbody>
</table>

DMP 115-416
A total of 32 patients received a mean Definity dose of 1.0 mL (range 0.5-1.5mL) with a weight-based mean dose of 11.73 microL/kg (range 9.09-25.59 microL/kg). 16 patients received more than the label recommended dose.

The 16 patients who had pulmonary hypertension at baseline received a mean Definity dose of 0.91 mL (range 0.5-1.3 mL) with a weight-based mean dose of 11.38 microL/kg (range 9.09-20 microL/kg). Seven of these patients received more than the label recommended dose.

The 16 patients who had normal pulmonary pressures at baseline received a mean Definity dose of 1.09 mL (range 0.7-1.5 mL) with a weight-based mean dose of 12.1 microL/kg (range 9.52-25.59 microL/kg). Nine of these patients received more than the label recommended dose.

More patients in this trial were under 65 years of age. More patients were male in the normal pulmonary pressure group, but more patients were female in the pulmonary hypertension group. The majority of patients were white (Table 18).
Table 18: DMP 115-416 - Demographics

<table>
<thead>
<tr>
<th></th>
<th>Pulmonary Hypertension (n=16)</th>
<th>Normal (n=16)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>57.4±15.1</td>
<td>56.9±10.8</td>
</tr>
<tr>
<td>≥65</td>
<td>68.8%</td>
<td>68.8%</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>56.3%</td>
<td>37.5%</td>
</tr>
<tr>
<td>Female</td>
<td>43.8%</td>
<td>62.5%</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>62.5%</td>
<td>68.8%</td>
</tr>
<tr>
<td>African American</td>
<td>25.0%</td>
<td>0%</td>
</tr>
<tr>
<td>Other</td>
<td>12.5%</td>
<td>31.3%</td>
</tr>
</tbody>
</table>

DMP 115-418

A total of 16,223 patients who received Definity in association with an echocardiogram were included in this retrospective database review. Patients who underwent stress echocardiography only were excluded, however some patients included in the evaluation may have undergone rest and stress echocardiography. Specific dose information was not available in the database.

More patients in this trial were 65 years of age or older. More patients were male. Most patients were white. There are some differences in demographics between the noncontrast and Definity groups, but the analyses in this trial used propensity score techniques to match patients to account for these differences (Table 19).

Table 19: DMP 115-418 - Demographics

<table>
<thead>
<tr>
<th></th>
<th>Noncontrast (n=991,983)</th>
<th>Definity (n=16,223)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>66.8±15.5</td>
<td>65.0±13.9</td>
</tr>
<tr>
<td>≥65</td>
<td>40.2%</td>
<td>46.6%</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>51.8%</td>
<td>63.5%</td>
</tr>
<tr>
<td>Female</td>
<td>48.2%</td>
<td>36.5%</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>64.8%</td>
<td>73.9%</td>
</tr>
<tr>
<td>African American</td>
<td>14.3%</td>
<td>11.2%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>4.9%</td>
<td>1.6%</td>
</tr>
<tr>
<td>Other</td>
<td>16.1%</td>
<td>13.4%</td>
</tr>
</tbody>
</table>

4 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page
7.2.2 Explorations for Dose Response

Data from DMP 115-415, the observational study of 1053 patients who received Definity in routine medical practice, was broken down by dose strata. No relationship between dose and adverse event reporting rate was identified.

7.2.3 Special Animal and/or In Vitro Testing

No animal or in-vitro testing was performed as part of this supplementary application.

7.2.4 Routine Clinical Testing

Routine clinical testing was adequate.

7.2.5 Metabolic, Clearance, and Interaction Workup

No pharmacologic assessments were made as part of this supplementary application.

7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class

Data on the safety of Optison were provided by its manufacturer in a briefing package and were presented at the May 2, 2011 FDA Advisory Committee meeting. A similar
adverse event profile is observed for Optison. Serious adverse events observed in clinical trials and spontaneous postmarketing reporting are typically cardiopulmonary or anaphylactoid in nature, and commonly occur within minutes of administration. Similar to Definity, there are many confounding factors and concomitant interventions in the population in which Optison is used which makes elucidation of causality very difficult.

7.3 Major Safety Results

7.3.1 Deaths

DMP 115-415
No deaths were observed in this trial.

DMP 115-416
No deaths were observed in this trial.

DMP 115-418
In this retrospective database review, 353 total fatalities are reported in patients who received Definity in the same hospitalization, though establishing causality is not possible given the limitations of the billing database used. A total of 25,626 fatalities are reported in patients who underwent noncontrast echocardiograms in the same hospitalization (Table 26).

Table 26: DMP 115-418 - Mortality in All Patients

<table>
<thead>
<tr>
<th></th>
<th>Definity</th>
<th>Noncontrast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>16,223</td>
<td>991,983</td>
</tr>
<tr>
<td>Deaths</td>
<td>353</td>
<td>25,626</td>
</tr>
<tr>
<td>Death Rate</td>
<td>2.18%</td>
<td>2.58%</td>
</tr>
</tbody>
</table>

Mortality in matched contrast and noncontrast datasets after propensity score matching techniques were applied is provided for both sponsor and FDA analysis (Table 27).

Table 27: DMP 115-418 - Mortality in Matched Datasets

<table>
<thead>
<tr>
<th></th>
<th>Sponsor Analysis</th>
<th>FDA Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Definity</td>
<td>Noncontrast</td>
</tr>
<tr>
<td><strong>Patients</strong></td>
<td>15,798</td>
<td>15,798</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td>338</td>
<td>488</td>
</tr>
<tr>
<td><strong>Death Rate</strong></td>
<td>2.14%</td>
<td>3.09%</td>
</tr>
<tr>
<td><strong>Same Day or Next Day Mortality</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td>2321</td>
<td>2616</td>
</tr>
<tr>
<td><strong>Death Rate</strong></td>
<td>14.69%</td>
<td>16.56%</td>
</tr>
</tbody>
</table>
7.3.2 Nonfatal Serious Adverse Events

**DMP 115-415**
No serious adverse events were observed in this trial.

**DMP 115-416**
No serious adverse events were observed in this trial.

**DMP 115-418**
Serious adverse events were not reported in the database used in this retrospective analysis.
7.3.3 Dropouts and/or Discontinuations

DMP 115-415
A total of seven patients were discontinued prior to receiving Definity, five because of inability to obtain IV access, one because of a ventricular septal defect, and one because of patient withdrawing consent. No discontinuations were due to adverse events or protocol violations.

DMP 115-416
Two patients were discontinued prior to receiving Definity. One patient required an urgent intervention and one patient met exclusion criteria of baseline pulmonary arterial systolic pressure greater than 75 mmHg. No dropouts or discontinuations occurred after receiving Definity.

DMP 115-418
Not applicable in this retrospective database review.
7.3.4 Significant Adverse Events

DMP 115-415
No significant adverse events were observed in this trial.

DMP 115-416
One patient experienced two adverse events, lower back pain and headache, that were moderate in intensity and were considered possibly related to Definity. These adverse events were also considered possibly related to pulmonary arterial catheterization. These adverse events resolved with medication.

DMP 115-418
Adverse events were not reported in the database used in this retrospective analysis.
7.4 Supportive Safety Results

7.4.1 Common Adverse Events

DMP 115-415
Based on reviewer analysis of raw data, adverse events were observed in 10.7% of patients with 4.3% of patients experiencing adverse events that were considered possibly related to Definity. These numbers are similar to those reported by the sponsor with slight differences likely related to the reviewer’s exclusion of five patients without dosing information. 85% of the observed adverse events occurred within 30 minutes of administration. The vast majority were mild or moderate in intensity with very few being severe in intensity. No relationship between dose and adverse event rate was observed (Figure 20).

Figure 20: DMP 115-415 - Adverse Events

The most common adverse events with a reporting rate greater than 0.5% are below (Table 34).
DMP 115-415
Table 34: DMP 115-415 - Most Common Adverse Events

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>1.2%</td>
</tr>
<tr>
<td>Nausea</td>
<td>0.9%</td>
</tr>
<tr>
<td>Back Pain</td>
<td>0.7%</td>
</tr>
<tr>
<td>Tremor</td>
<td>0.6%</td>
</tr>
<tr>
<td>Angina Pectoris</td>
<td>0.5%</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>0.5%</td>
</tr>
<tr>
<td>Palpitations</td>
<td>0.5%</td>
</tr>
<tr>
<td>Ventricular Extrasystoles</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0.5%</td>
</tr>
<tr>
<td>Flushing</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

DMP 115-416
Nine patients experienced adverse events in this trial, four in the normal pulmonary pressure group and five in the pulmonary hypertension group. One patient in the normal pulmonary pressure group experienced two adverse events (lower back pain and headache) that were moderate in intensity and which resolved with medication. The remainder of the adverse events were mild in intensity.

The most common adverse events occurring in more than 0.5% of patients are listed below. Because of the relatively small number of patients in this trial, all adverse events reported have an incidence of greater than 0.5% (Table 35).

Table 35: DMP 115-416 - Most Common Adverse Events

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myalgia</td>
<td>15.6%</td>
</tr>
<tr>
<td>Lower Back Pain</td>
<td>6.3%</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>3.1%</td>
</tr>
<tr>
<td>Neck Pain</td>
<td>3.1%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3.1%</td>
</tr>
<tr>
<td>Headache</td>
<td>3.1%</td>
</tr>
</tbody>
</table>

DMP 115-418
Adverse events were not reported in the database used in this retrospective analysis.
7.4.2 Laboratory Findings

DMP 115-415
Laboratory measures were not evaluated in this trial.

DMP 115-416
No clinically important chemistry or hematology laboratory changes were observed in this trial. Interesting, but inconclusive, changes in some immunologic parameters were seen and are described below (Section 7.4.6).
7.4.3 Vital Signs

DMP 115-415
No clinically important vital sign changes were seen in this trial. A representative chart of vital sign changes over time is provided below. In this chart, change in mean heart rate is shown at various timepoints after Definity administration. The blue line connects the mean change. The red boxes represent the 25-75th percentiles. The whiskers represent the 10-90th percentiles. The dots represent individual patients or clusters of patients and are provided to give a sense of individual variability. The chart is divided into those patients that underwent rest echocardiography and those patients who underwent stress echocardiography. As expected, heart rate increases during stress followed by recovery over time. In both cases, there is some expected individual variability, but no concerning patterns. Similar findings were seen for other vital sign measurements (Figure 21).

Figure 21: DMP 115-415 - Heart Rate Over Time

DMP 115-416
No clinically important changes were seen in pulmonary nor systemic hemodynamic parameters in either patients with normal baseline pulmonary pressures or patients with pulmonary hypertension. Some individual variability was seen for each of the parameters, but no clear patterns were seen. A representative chart of mean systolic pulmonary arterial pressure over time is displayed. Patients with normal pulmonary pressures are on the left and patients with pulmonary hypertension are on the right.
The red lines connect the mean values over time and the black bars represent 95% confidence intervals (Figure 22).

Figure 22: DMP 115-416 - Mean Systolic Pulmonary Arterial Pressure Over Time

Normal (PASP<=35mmHg)  Pulm Htn (PASP>35mmHg)

Reference ID: 2977168
7.4.4 Electrocardiograms (ECGs)

DMP 115-415

No clinically significant ECG changes were observed in this trial. A substantial number of ECG interpretations changed from normal to abnormal or demonstrated a new cardiac abnormality after the stress dose, particularly early in stress, but most of these changes were rhythm changes such as sinus tachycardia, premature ventricular contractions, or premature atrial contractions. These changes are expected during stress testing and in a patient population with underlying cardiac conditions. Small percentages of ECG interpretations changed from normal to abnormal in the rest population (Table 39).

Table 39: DMP 115-415 - ECG Changes

<table>
<thead>
<tr>
<th></th>
<th>Rest Dose</th>
<th>Stress Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 Min</td>
<td>15 Min</td>
</tr>
<tr>
<td>Overall Interpretation</td>
<td>409 (52.0%)</td>
<td>415 (59.6%)</td>
</tr>
<tr>
<td>Normal at Baseline That Remain Normal</td>
<td>415 (44.3%)</td>
<td>258 (37.1%)</td>
</tr>
<tr>
<td>Normal at Baseline That Become Abnormal</td>
<td>21 (2.2%)</td>
<td>23 (3.3%)</td>
</tr>
<tr>
<td>Patients Developed a New Cardiac Rhythm Abnormality*</td>
<td>15 (1.6%)</td>
<td>12 (1.7%)</td>
</tr>
</tbody>
</table>

*Patient develops a type of ECG abnormality that was not reported on pre-dose page.

The QT interdisciplinary review team was consulted regarding these data. The reported that the data is inconclusive because no central over-read was performed and ECG data was not collected at appropriate timepoints.

DMP 115-416

ECGs were obtained at baseline and two hours after Definity administration. Baseline abnormalities were noted in a number of patients which is expected in this patient population. No clinically significant variations in interpretation were observed. No clinically significant changes in QT, QTc, QRS, PR, or RR intervals were seen.

The QT interdisciplinary review team was consulted regarding these data. The reported that the data is inconclusive because no central over-read was performed and ECG data was not collected at appropriate timepoints.
7.4.5 Special Safety Studies/Clinical Trials

7.4.6 Immunogenicity

DMP 115-416
Several immunologic laboratory measures were obtained in this trial. The mean complement C3a level at three minutes after Definity administration was significantly higher than at baseline, and subsequently slowly trended downwards towards baseline over time. Mean white blood cell levels decreased at three minutes after Definity administration, though this change was not significant. These findings were suggestive of complement activation with white cell migration which could represent activation of the immune system.

However, at three minutes prior to administration, the complement C3a level was actually higher than at three minutes after administration, though not significantly different due to a wide 95% confidence interval. The wide confidence interval appears to be related to at least one outlier measurement at this timepoint, though even after removal of the outlier the mean value at three minutes prior to administration is not significantly different than at three minutes after administration. In this trial, 1239 ng/mL was the upper limit of normal (Figure 30).

Figure 30: DMP 115-416 - Mean Immunology Parameters
7.5 Other Safety Explorations

7.5.1 Dose Dependency for Adverse Events

DMP 115-415
When patients were stratified by Definity dose, no relationship between dose and adverse event rate was observed.

7.5.2 Time Dependency for Adverse Events

The sponsor reports on their clinical trial experience in the setting of stress. Postmarketing data is also available, of which a substantial portion of patients were probably exposed in the setting of stress. Many serious adverse events occur within 30 minutes of administration (Table 40).

Table 40: Time Dependency of Adverse Events

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Within 30 minutes</th>
<th>Within 60 minutes</th>
<th>More than 60 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials in Stress</td>
<td>SAE</td>
<td>10</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Postmarketing Experience</td>
<td>Deaths</td>
<td>22</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>SAE*</td>
<td>330</td>
<td>184</td>
<td>187</td>
</tr>
</tbody>
</table>

* 133 unclear time to onset
* One postmarketing report was a medication/labeling error

7.5.3 Drug-Demographic Interactions

DMP 115-415
Adverse event rates were similar when patients less than 65 years of age are compared to those who are 65 years of age or greater. A higher adverse event rate was observed in females compared to males. Variable adverse event rates in the various ethnic subgroups are somewhat difficult to interpret because of the relatively low number of non-Caucasian patients in this trial (Table 41).

Table 41: DMP 115-415 - Subgroup Adverse Event Rate

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Adverse Event Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>10.7%</td>
</tr>
<tr>
<td>&lt;65</td>
<td>10.4%</td>
</tr>
<tr>
<td>≥65</td>
<td>10.6%</td>
</tr>
<tr>
<td>Male</td>
<td>8.8%</td>
</tr>
<tr>
<td>Female</td>
<td>13.3%</td>
</tr>
<tr>
<td>Caucasian</td>
<td>11.1%</td>
</tr>
<tr>
<td>African American</td>
<td>6.7%</td>
</tr>
<tr>
<td>Asian</td>
<td>15.4%</td>
</tr>
<tr>
<td>Other</td>
<td>9.7%</td>
</tr>
</tbody>
</table>
7.5.4 Drug-Disease Interactions

The submitted trials were not designed nor powered to evaluate drug-disease interactions. Definity is typically administered infrequently and as a single dose which makes this less of a concern.

7.5.5 Drug-Drug Interactions

The submitted trials were not designed nor powered to evaluate drug-drug interactions. Definity is typically administered infrequently as a single dose, and has a short half-life, which makes this less of a concern.

7.6 Additional Safety Evaluations

7.6.1 Human Carcinogenicity

Carcinogenicity is not a concern given the dosing scheme of Definity.

7.6.2 Human Reproduction and Pregnancy Data

Definity is considered Pregnancy Category B. No adequate and well-controlled studies of Definity have been performed in pregnant women. Nonclinical reproductive studies revealed no evidence of impaired fertility or harm to the fetus due to Definity.

This submission did not further address human reproduction or pregnancy concerns.

1 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page
7.6.4 Other Subgroup Analyses

Adverse event rates appear to be similar across age groups, gender, and race when the entire clinical trial and postmarketing experience is considered. No clear pattern for any particular subgroup is identified.

7.6.5 Overdose, Drug Abuse Potential, Withdrawal and Rebound

Not applicable given the dosing scheme for Definity.

7.7 Additional Submissions / Safety Issues

DMP 115-418
As discussed in Appendix 9.3, Advisory Committee, below, this study had critical limitations that limited its usefulness.
8 Postmarket Experience

8.1 Deaths

A total of 22 unique postmarketing deaths have been reported in association with Definity as of the end of 2010. Of these 22 deaths, 14 occurred within 30 minutes of administration and 17 occurred within 60 minutes of administration. Four of these deaths were clearly associated with stress testing, two with exercise and two with dobutamine. The majority of these deaths appeared to be cardiopulmonary and/or anaphylactoid in nature and were typically followed by cardiac arrest or coding. Example descriptions of several of these deaths are provided (Table 42).

Table 42: Definity - Example Postmarketing Fatal Adverse Event Reports

<table>
<thead>
<tr>
<th>Causality (reporter assessment)</th>
<th>Example Fatal Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS</td>
<td>“infusion reaction shortly after administration [with] full cardiac arrest 15 minutes after receiving perflutren.”</td>
</tr>
<tr>
<td>PS</td>
<td>“Approximately 3 minutes after administration, he complained of a sensation of ‘tingling’... the patient was centrally cyanotic, unresponsive, and apparently seizing. The physician felt this was likely a hypersensitivity reaction...despite aggressive and prolonged resuscitative efforts, the patient expired.”</td>
</tr>
<tr>
<td>PS</td>
<td>“After 4 minutes of perflutren administration, the patient developed what appeared to be an anaphylactoid reaction with a fatal outcome.”</td>
</tr>
</tbody>
</table>

* PS = primary suspect agent

8.2 Adverse Events

A total of 1340 adverse events are reported in the AERS database as of February 14, 2011 where Definity was reported as the primary or secondary suspect drug with a peak
number of adverse events of 393 reported in 2007. Of all adverse events, 264 were reported as serious adverse events with a peak of 68 reported in 2007.

Many of these adverse events appeared to be cardiopulmonary or anaphylactoid in nature and of those with time information, many appeared to occur shortly after administration. Example descriptions of several of these events is provided (Table 43).

### Table 43: Definity - Example Postmarketing Adverse Event Reports

<table>
<thead>
<tr>
<th>Causality (reporter assessment)</th>
<th>Example Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS</td>
<td>“...[patient] developed flushing, redness, shortness of breath, hypotension, and a drop in oxygen level less than one minute after receiving Definity...”</td>
</tr>
<tr>
<td>PS</td>
<td>“...experienced pain and coded after receiving a diluted bolus of 1.3mL of perflutren... He began to experience pain within 1 minute of the introduction of perflutren.”</td>
</tr>
<tr>
<td>PS</td>
<td>“...developed life-threatening ventricular fibrillation 2 minutes after receiving two doses of perflutren...”</td>
</tr>
</tbody>
</table>

* PS = primary suspect agent

### 8.3 Utilization
9 Appendices

9.1 Literature Review/References


9.2 Labeling Recommendations

Boxed Warning
Recommend keeping the boxed warning, but including the word “uncommon” as an estimate of the rate of serious adverse reactions to Definity. We also recommend removing the specific pulse oximetry and ECG monitoring requirements and replacing them with a general observation recommendation.

1 Indications and Usage
Recommend removing the statement that safety and efficacy with stress have not been established. Otherwise, the indication should remain the same.

4 Contraindications
The Contraindications section should remain the same.

5 Warnings and Precautions
Recommend changing the language to be consistent with the boxed warning and updating the list of symptoms observed.

6 Adverse Reactions
6.2 Postmarketing Experience
Recommend updating the list of terms based on new reports.
8 Use in Specific Populations

8.1 Pregnancy
Recommend updating this section to be compatible with new requirements. No new pregnancy data is submitted.

8.2 Labor and Delivery
Recommend omitting this section upon consultation with the maternal health team as no relevant data is available.

8.3 Nursing Mothers
Recommend updating this section in consultation with the maternal health team based on known pharmacodynamics of Definity.

8.4 Pediatric Use

8.5 Geriatric Use
Recommend updating this section to provide actual numbers of patients studied in the geriatric subgroup.

9 Drug Abuse and Dependence
Recommend omitting this section as it is not relevant.

14 Clinical Studies
Recommend including the results of the postmarketing safety registry and pulmonary hemodynamic studies as these studies were relatively robust and support safety labeling changes.

Formatting
Recommend updating the label to Physician Labeling Rule format.

9.3 Advisory Committee Meeting
A joint meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees was held on May 2, 2011. The focus was on safety data related to three ultrasound contrast agents, Definity and Optison which are currently approved in the U.S., and SonoVue which is approved elsewhere but currently has investigational status in the U.S. Emphasis was placed on interval safety data since the prior Advisory Committee meeting related to the safety of these agents which was held on June 24, 2008.

The sources of data included three postmarketing studies that Lantheus Medical Imaging and GE Healthcare performed for their ultrasound contrast agents, Definity and Optison, respectively. Postmarketing reporting data since approval was also reviewed.
for both agents. Bracco Diagnostics provided a summary of their clinical trial and foreign postmarketing experience for SonoVue.

In regards to the three postmarketing studies for Definity and Optison, one clear conclusion from the committee was that the retrospective database reviews had multiple critical limitations that significantly limited their usefulness. There was a brief discussion about how one might re-analyze this data or re-perform these studies, but ultimately this was felt to be of limited usefulness. The observational studies were felt to be more useful, though they were limited by their lack of control and by their relatively low numbers of patients, particularly when attempting to quantify risk for rare events. Finally, the pulmonary hemodynamic studies, while also limited in numbers, were felt to provide reasonable assurance that no clinically important hemodynamic changes are seen after Definity or Optison administration. Overall, even given the limitations of these trials, the Committee concluded the trials were useful in ruling out a high rate of serious events.

The Committee agreed that serious adverse events and fatalities continue to be observed in spontaneous postmarketing reporting. Though causality is very difficult to assess because of significant comorbidities, concomitant medications, and in some cases associated stress procedures, the common pattern and typically short time period from administration to event was concerning. There are many limitations and uncertainties in calculating event rates from this data, but the Committee seemed reasonably assured that these events were uncommon.

There was a somewhat mixed response in the discussion over whether the boxed warning was still necessary. Some felt that while there were limitations in the postmarketing trials and postmarketing reporting, the event rates appeared low enough that a boxed warning might not be necessary. Others felt that the seriousness and concerning pattern of events warranted highlighting these concerns to clinicians. Several members noted that while the sponsors and some clinicians suggested the boxed warning was hampering use of these agents, the sales data, at least for Definity, showed a rebound after the initial labeling changes in 2007 and 2008. Most members felt that the specific monitoring requirements in the boxed warning were somewhat onerous and could perhaps be modified.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------------------------------
ROSS W FILICE
07/21/2011

---------------------------------------------
LIBERO L MARZELLA
07/22/2011
# Summary Review for Regulatory Action

**Date**: July 26, 2011  
**From**: Dwaine Rieves, MD  
**Subject**: Division Director Summary Review  
**NDA/BLA #**: 021-064/efficacy supplement under 505b2  
**Applicant Name**: Lanthenes Medical Imaging  
**Date of Submission**: September 29, 2010  
**PDUFA Goal Date**: July 29, 2011  
**Proprietary Name / Established (USAN) Name**: DEFINITY/Vial for Perfluorin Lipid Microsphere Injectable Suspension  
**Dosage Forms / Strength**: No new dosage proposed; current dosage is 10 mcL/kg bolus injection with option for second dose; may also be administered as an infusion as described in current labeling  
**Proposed Indication(s)**: “Activated DEFINITY (Perfluorin Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.”  
**Action/Recommended Action**: Complete Review-response

<table>
<thead>
<tr>
<th>Material Reviewed/Consulted</th>
<th>Names of discipline reviewers</th>
</tr>
</thead>
<tbody>
<tr>
<td>OND Action Package, including:</td>
<td></td>
</tr>
<tr>
<td>Medical Officer Review</td>
<td>Ross Filice, MD &amp; Louis Marzella, MD, PhD (CDTL)</td>
</tr>
<tr>
<td>Statistical Review</td>
<td>Janelle Charles, PhD &amp; LaRee Tracy, PhD (TL)</td>
</tr>
<tr>
<td>Pharmacology Toxicology Review</td>
<td>Not applicable/no data</td>
</tr>
<tr>
<td>CMC Review/OBP Review</td>
<td>Not applicable/no data</td>
</tr>
<tr>
<td>Microbiology Review</td>
<td>Not applicable/no data</td>
</tr>
<tr>
<td>Clinical Pharmacology Review</td>
<td>Christy John, PhD &amp; Y. Gene Williams, PhD (TL)</td>
</tr>
<tr>
<td>DDMAC</td>
<td>James Dvorsky</td>
</tr>
<tr>
<td>DSI</td>
<td>Not applicable/no inspections</td>
</tr>
<tr>
<td>CDTL Review</td>
<td>Louis Marzella, MD, PhD</td>
</tr>
<tr>
<td>OSE/DMEPA</td>
<td>Not applicable</td>
</tr>
<tr>
<td>OSE/DDRE</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Pediatric and Maternal Health</td>
<td>Upasana Bhatnager, MD, Jeanine Best &amp; Karen Feibus, MD (TL)</td>
</tr>
<tr>
<td>Consultative Reviewer</td>
<td>Suchitra Balakrishnan/CardioRenal Drugs</td>
</tr>
<tr>
<td>Project Manager</td>
<td>Frank Lutterodt</td>
</tr>
</tbody>
</table>

OND=Office of New Drugs  
DDMAC=Division of Drug Marketing, Advertising and Communication  
OSE=Office of Surveillance and Epidemiology  
DMEPA=Division of Medication Error Prevention and Analysis

Reference ID: 2980843
1. Introduction:

Definity is a “microbubble” contrast agent used in echocardiography to enhance visualization among patients with suboptimal echocardiograms. Importantly, most patients have adequate echocardiographic visualization without the use of a contrast agent. This is an important consideration because both approved echocardiographic contrast agents (Definity and Optison) have been associated with uncommon but serious cardiovascular reactions. These reactions prompted the addition of a boxed warning to the labeling in 2007 along with new contraindications other safety information. Subsequently, accumulating information led to a revision of the labeling to remove some of the contraindications (2008); this labeling approval was accompanied with a commitment for the sponsor to complete at least three clinical studies:

a) a study of pulmonary hemodynamics;

b) a retrospective/observational study of the use of Definity among critically ill patients;

c) complete a previously requested post-marketing “registry” study of Definity “in actual clinical use.”

The current submission includes the three requested clinical study results plus:

The safety data were discussed at a May 2, 2011 meeting of the Cardiovascular and Renal Drugs Advisory committee. The most notable advice from the Committee was the citation of many limitations within the observational study conducted among critically ill patients. The advisors expressed opinions that generally indicated these study results were not useful and potentially misleading due to uncontrolled bias as well as other limitations associated with the retrospective design.

The review team supplied proposed labeling text to the sponsor late in the review cycle. The supplied labeling text built upon the physicians labeling rule format (PLR format) the sponsor had originally supplied with
the application. The sponsor expressed an opinion that consequently, the review has culminated in a complete review letter.

2. Background:

The initial development of Definity occurred among patients who had few underlying co-morbidities. This consideration prompted the FDA to request (and the sponsor agreed to) a post-marketing commitment to study Definity “as it is actually used in clinical practice.” (from 2001 approval letter). However, this commitment was not fulfilled by the time post-marketing reports had begun to show serious (and sometimes fatal) reactions shortly following Definity administration (reports that culminated in the 2007 label revision). The reports of the serious reactions generally involved patients with fairly severe underlying co-morbidities (i.e., the types of conditions that would have generally excluded patients from premarketing studies). The FDA was also concerned in 2007 by the reports of pulmonary hypertension in animal models.

Ultimately, the FDA worked with the sponsor to develop a plan to obtain clinical data that helped to better characterize the safety of Definity. This supplement contains this safety data.

3. Chemistry, Manufacturing and Controls:

No new information.

4. Nonclinical Pharmacology/Toxicology:

No nonclinical data were submitted.

5. Clinical Pharmacology/Biopharmaceutics:

I concur with the conclusions reached by Drs. Christy John and Gene Williams regarding the necessary text for the PLR format.

No new clinical pharmacology data were provided.

6. Clinical Microbiology:

No new data.

7. Clinical/Statistical-Efficacy:

Dr. Ross Filice provided the main clinical review and Dr. Louis Marzella provided the Cross Discipline Review.
Dr. Janelle Charles provided the main statistical review and Dr. Laree Tracy provided the supervisory review.

The application included the following main data sources:

<table>
<thead>
<tr>
<th>Study</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMP 115-415</td>
<td>Phase IV registry study of Definity in clinical practice</td>
</tr>
<tr>
<td>DMP 115-416</td>
<td>Pulmonary hemodynamics</td>
</tr>
<tr>
<td>DMP 115-418</td>
<td>Retrospective, observational database study of critically ill patients</td>
</tr>
</tbody>
</table>

The data contained multiple deficiencies as summarized here and excerpted from the complete review letter.
4. Regarding the proposed alterations of safety information within the prescribing information:

a. The supplied information importantly contributes to the assessment of the safety of Definity. This information appears to support some of the proposed changes to the label. However, we do not agree with elimination of the boxed warning. We supplied the sponsor with a draft version of potentially acceptable labeling during the review cycle.

b. Once the sponsor has addressed these concerns, we encourage the submission of revised labeling that either incorporates the edits we previously supplied or justifies alternative text.

c. The safety data sources consisted of a pulmonary hemodynamic study (DMP 115-416), a “registry” study (DMP 115-415), an observational study of Definity use among critically ill patients (DMP 115-418), and post-marketing pharmacovigilance data. With the exception of the observational study (DMP 115-418), we regard these data sources as providing summary information appropriate for inclusion within the prescribing information, as illustrated by the draft text we proposed during the review cycle. As discussed at the May 2, 2011 Advisory Committee meeting, the observational study (DMP 115-418) has several important limitations that render the study conducive to misinterpretation; we do not regard this study’s findings as appropriate for inclusion within the prescribing information.
8. Safety:

As noted above, the supplied safety data provide useful information regarding the potential for adverse reactions to Definity. The data importantly detected no signal for pulmonary hemodynamic alterations (among relatively “stable” patients). Together, the review team concluded that modification of the prescribing information was appropriate to include some of the supplied safety data. The team did not concur with the sponsor’s proposal to remove the boxed warning.

Post-marketing Requirements (PMR): none

Post-marketing Commitments: none

9. Advisory Committee Meeting:

Safety was discussed at a May 2, 2011 advisory committee, as noted above.

10. Pediatrics:

11. Other Relevant Regulatory Issues:

No inspections were performed. Consultation was provided by the CardioRenal Drug Products review division.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAFEL D RIEVES
07/28/2011
1. Introduction

**Definity: labeled indications**
Definity (Perflutren Lipid Microsphere) Injectable Suspension is a diagnostic ultrasound contrast agent approved on July 31, 2001 for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. The Definity indication statement cautions that the safety and efficacy of Definity with exercise stress or pharmacologic stress testing have not been established.

**Definity: drug product**
The perflutren lipid microspheres are composed of octafluoropropane gas encapsulated in an outer lipid shell. After activating the contents of the vial in a proprietary mixer each mL of the milky white suspension contains a maximum of $1.2 \times 10^{10}$ perflutren lipid microspheres, and about 150 microL/mL (1.1mg/mL) octafluoropropane. The mean diameter of the microspheres ranges from 1.1µm-3.3µm with a maximum diameter of 20 µm and with 98% of the microspheres having a diameter of less than 10 µm. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.
Supplemental NDA: objectives
On September 29, 2010 Lantheus Medical Imaging (the Applicant) submitted a supplemental New Drug Application with data on the use of Definity in:

- current clinical practice (postmarketing commitment, PMC)
- critically ill patients (postmarketing requirement, PMR)
- patients with normal and elevated pulmonary artery pressure (postmarketing requirement)

Supplemental NDA: proposed labeling
This submission also included a reformatted Definity Package Insert (PI) in Physician Labeling Rule format. The Applicant proposed extensive revisions to the following sections of the PI.

Supplemental NDA: data sources
The principal objectives of the present supplemental application can be summarized as follows: important label updates on the safety of Definity in the critically ill and in the clinical use population, The data streams for these objectives with emphasis on their methodological weaknesses are outlined below.
Definity safety studies
The submission also contains important data requested by FDA under the FDA Amendment Acts (as PMR) or negotiated with the Applicant (an outstanding PMC) for assessing the safety of Definity in critically ill patients and in the current clinical use population. The submission contains the following complete study reports.

- DMP 115-415 (Registry Study) is a prospective open-label surveillance registry study of Definity in 1053 patients in clinical practice. Adverse events, vital signs, and ECG data were captured.

- DMP 115-416 (Pulmonary Hemodynamic Study) is a prospective open-label nonrandomized clinical study of Definity in patients (16 with elevated and 16 with normal pulmonary artery pressure) during rest echocardiography. The study evaluated pulmonary hemodynamics. Adverse events, vital signs, ECGs, and laboratory measurements were also evaluated. The study conduct was good and the clinical reviewer determined that the quality of the data was acceptable.

- DMP 115-418 (Retrospective Database Study) is a retrospective study of critically ill patients. Mortality outcome data from 16223 critically ill patients (full dataset analysis) who received Definity with rest transthoracic echocardiography were compared to patients with noncontrast echocardiography using propensity scores matching techniques.

FDA and the Applicant agreed on the design of these studies. These studies were designated as postmarketing commitment or requirements and were the focus of an advisory committee meeting. The clinical and statistical reviewers in their reviews highlight several important limitations inherent in the data source and methodology of these postmarketing studies. These limitations would not permit the development of reliable estimates of the incidence of serious reactions associated with the use of Definity. Nevertheless, the clinical reviewer believes that the study results will prove useful in supporting refinement of the label with respect to information on likelihood of risk in critically ill patients, and recommendations for monitoring for adverse reactions (see Section 8 of this review). This assessment is generally consistent with the recommendations made by an FDA advisory committee convened to discuss the data from the PMC/PMR studies for Definity and for the other approved ultrasound contrast agent Optison manufactured by GE Healthcare (see Section 9 of this review). The CDTL agrees with these assessments.
2. Background

Important safety considerations
Because ultrasound contrast agents contain numerous small microspheres, there have been concerns related to microvascular obstruction. Preclinical data had shown the potential for these agents to induce pulmonary hypertension particularly in porcine models; however relevant clinical safety studies were not performed before the approval of Definity. In addition the patient population evaluated in the clinical development program of Definity did not include critically ill patients. Therefore the manufacturer agreed as a postmarketing commitment to evaluate Definity in actual clinical use. However the conduct of the study was delayed.

In 2006 and 2007, FDA became aware of a number of deaths temporally related to the administration of Definity. These deaths generally followed cardiovascular collapse or a hypersensitivity reaction and occurred predominantly in patients with underlying cardiac or pulmonary disease. Because of these findings, a number of modifications were made to the Definity label including addition of boxed warnings and new contraindications. The primary clinical reviewer (Dr. Filice) discusses in detail the labeling changes in 2007 and 2008.

To further characterize the risks involved FDA required two postmarketing clinical studies:

- A study that will utilize an existing database to compare in hospital mortality in critically ill patients undergoing echocardiography with and without the sponsor’s ultrasound contrast agent.
- A clinical trial that, at a minimum, provides pulmonary hemodynamic data from at least 30 patients with known or suspected cardiac disease who are undergoing an echocardiogram with the sponsor’s ultrasound contrast agent.

The applicant also agreed to perform as a postmarketing commitment:

- A study of at least 1000 patients undergoing echocardiography with the sponsor’s ultrasound contrast agent in routine clinical practice.
3. CMC/Device

The supplemental application makes no changes to the drug substance, the drug product or their tests and specifications. Therefore no CMC review was necessary. No new devices are proposed for use in this application.

4. Nonclinical Pharmacology/Toxicology

No new Pharmacology/Toxicology data were needed and none were provided.

5. Clinical Pharmacology/Biopharmaceutics

The submission contains no new clinical pharmacology data. The FDA clinical pharmacology reviewer (Dr. John) recommended changes to the format of the clinical pharmacology section of the package insert. Dr John recommended approval of the supplement from the Clinical pharmacology perspective.

6. Clinical Microbiology

Not applicable.

7. Clinical/Statistical- Efficacy

3 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page
8. Safety

Definity registry study
The study was adequately designed to assess potential acute adverse reactions and clinical and laboratory abnormalities. No deaths or serious adverse events were observed in 1053 patients in the prospective safety registry. Adverse events were observed overall in 11% of patients. The safety monitoring procedures did not identify subclinical abnormalities in a broader patient population than the population studied in the premarket phase. The reviewer recommends that these data be cited in the package insert and that the monitoring recommendations in the product label be lessened.

Definity studies in critically ill patients
Pulmonary Hemodynamic Study
The pulmonary hemodynamic study did not show clinically important hemodynamic changes in association with Definity. No deaths or other serious adverse events were observed in 32 patients. Only two adverse events in one patient were considered possibly related to Definity; the events were not clinically important. The clinical reviewer believes that this study fulfills the PMR and that the results can be cited in the label. For more detailed review of the pulmonary hemodynamic study, please see Dr. Filice’s review.

Retrospective Database Review Study
The study was designed to compare mortality in critically ill hospitalized patients who received contrast enhanced echocardiography and critically ill patients who underwent echocardiography without contrast. The study used discharge data of hospitalized patients from Premier’s Perspective database in patients with discharge data from January 1, 2002 to June 15, 2008.

The primary endpoint was 48-hour mortality defined as a discharge code of deceased on the same calendar day or day after echocardiography. The FDA statistical reviewer estimated lower mortality risk in Definity patients relative to patients who underwent echocardiography without contrast. There were 2.18% (353/16199) and 2.73% (443/16199) 48-hour deaths in the
Definity and non-contrast matched analysis groups respectively. The odds ratio (Definity to noncontrast) estimate of 48-hour mortality was 0.78, 95% CI (0.67, 0.90).

The database and methodology limitations inherent in the retrospective study have important limitations that do not allow reliance on the point estimates calculated. Nevertheless, the lack of safety signal in the study is noteworthy. The clinical reviewer believes that the study fulfills the PMR; however the limitations of the data preclude citing the data in the product label. The FDA reviewers’ conclusions and recommendation are consistent with the advice the FDA received at a joint Advisory Committee meeting on May 2, 2011 (see Section 9 of this review).

9. Advisory Committee Meeting

On June 24, 2008, the Cardiovascular and Renal Drugs Advisory Committee met to discuss the safety of ultrasound contrast agents. The Committee endorsed the proposed risk assessment plans for the approved ultrasound contrast agents (Definity and Optison).

On May 2, 2011 the Cardiovascular and Renal Drugs and the Drug Safety and Risk management Advisory Committees met to discuss the results of the postmarketing studies for Definity and Optison and to receive a safety update for SonoVue an ultrasound contrast agent that is investigational in the US and is marketed in Europe and Asia. For the full review of the relevant data please refer to the FDA’s and the Applicant’s briefing packages and presentations materials1.

Registry study. Several committee members felt the results of the safety registry were sufficiently informative to include them in labeling.

Pulmonary Hemodynamic Study. The Committee felt that the numbers of patients studied was small and that the pulmonary hypertension at baseline was not severe, but that these studies provided reasonable assurance that Definity do not cause important pulmonary hemodynamic changes. Several members of the committees felt the results of the studies could be included in the labeling.

Retrospective Database Review Study. The Committee noted that observational studies are important for assessing safety signals in the post-marketing phase, however, the databases from observational studies have important imitations (e.g. lack of precise time of or cause of death, potentially unequal matching due to hidden covariates). The results of the Applicant’s study are not robust and are difficult to interpret. Members commented on the use of propensity score matching and the lack of confidence in this matching technique to appropriately balance the different groups. The committee felt that the observational study data

1 http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm250295.htm
should not be included in the labeling based on the designs of the studies and the limitations of the results.

10. Pediatrics

11. Other Relevant Regulatory Issues

Consultations on pediatric and maternal health labeling

- The FDA maternal health team consultant (Dr. Bhatnagar) recommended adding to the label (Section 8.3 Nursing Mothers) a recommendation to pump and discard breast milk once after dosing because of the rapid clearance of the drug. The CTDL agrees with this recommendation.
Consultation on QT prolongation

The FDA consultant from the Division of Cardiorenal Drugs (Dr. Balakrishnan) evaluated the potential for QTc prolongation. The consultant reviewed the Definity label and the following two study reports.

The Definity label reports ECG interval data in 221 study subjects at time points from 1 to 72 hours after Definity bolus injection. QTc prolongations of >30 msec were noted in 64 (29%) subjects. Forty-six out of 64 subjects with QTc prolongations were further evaluated and 39% (18/46) showed associated cardiac rhythm changes. The consultant states that these findings are inconclusive because the ECGs were not obtained at the Tmax for Definity. In addition to be more informative the label needs to capture outliers with absolute change over 500 ms or over 60 ms change from baseline.

In study DMP 115-416 32 patients, 16 with normal pulmonary pressures and 16 with pulmonary hypertension underwent a resting echocardiogram with Definity along with pulmonary arterial catheterization; 12-lead ECGs were obtained before the echocardiogram and 2 hours+ 52 minutes after administration. Multiple intervals were measured (PR, RR, QRS, QT, and QTcB). The Applicant concluded that no clinically significant changes are seen in association with Definity administration.
The active moiety of Definity (octafluoropropane) declines monoexponentially after intravenous administration with a mean half-life of 1.3 minutes. The consultant found the ECG data to be inconclusive because the ECGs were not collected at Tmax (30-40 seconds post-dose), and even large ECG effects could not be excluded. Also in general single ECGs were recorded with no central over-read, therefore the values reported were not considered reliable.

The consultant took into account the short half-life of Definity, its use in monitored patients under supervision by personnel trained in arrhythmia management. Based on these considerations the consultant did not feel that a TQT study to quantify QT effects of Definity is required.

The CDTL agrees with these conclusions. The new data provided are inconclusive and do not need to be added to the label. The existing information in the present label seems to suggest a greater level of concern than warranted by the evidence. It might be useful to reevaluate the data from the 221 patient experience and to cite the numbers of patients with QTc absolute change >500 ms or over 60 ms from baseline as recommended by the consultant.

Financial disclosures/audits
Two investigators in study 415 and one investigator in study 415 and 416 reported payments greater than $25,000 for honoraria during the course of the studies. Approximately 15% of patients in study 415 and no patients in study 416 were enrolled by these investigators. These reports do not raise concerns about the integrity of the studies.

12. Labeling

The efficacy supplement triggered the revision of the package insert in Physician Labeling format. The Applicant proposed several efficacy and safety labeling changes (see Section 1 of this review). FDA communicated to the Applicant the following labeling comments:

- It is reasonable to remove the cautionary statement about stress testing from the Indications and Usage section of the label.
- The Boxed warning needs to be reinstated. New information about the incidence of severe reactions could be added. The requirements for monitoring could be lessened.
- Data from the prospective safety registry and the pulmonary hemodynamic study are appropriate for inclusion in the label. However data from the retrospective
observational study should not be included because of the important methodological concerns discussed by FDA at the advisory committee meeting.

FDA communicated to the Applicant the specific labeling language recommended. FDA and the Applicant did not reach agreement on the labeling. This lack of agreement led to the FDA decision to take a complete response action on the present supplemental application.

13. Recommendations/Risk Benefit Assessment

- Recommended Regulatory Action

In addition the FDA reviewers did not agree with the Applicant regarding the overall interpretation of the PMC/PMR study results. For these reasons the clinical reviewer recommends a complete response action for this efficacy supplement and the CDTL agrees with this recommendation.

- Risk Benefit Assessment

The CDTL agrees with Dr. Filice that the overall risk benefit profile for Definity for the approved use remains favorable.

- Recommendation for Postmarketing Risk Evaluation and Management Strategies

None are needed.

- Recommendation for other Postmarketing Requirements and Commitments

None are needed. Subsequent to the FDA clinical and statistical reviews of the complete reports of the Definity PMC/PMR studies, the CDTL recommends that the PMC/PMR be declared fulfilled.

- Recommended Comments to Applicant
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIBERO L MARZELLA
07/28/2011
DIVISION OF MEDICAL IMAGING PRODUCTS
Clinical Review Memorandum
Date: December 10, 2010
Sponsor: Lantheus Medical Imaging
Product: Definity (perflutren)
Regulatory submission: NDA-21064
Supporting Document: 204
Reviewer: Ross Filice, M.D. DMIP/ODE IV/CDER

Background
The sponsor has submitted as well as modifying current safety warnings.

Findings and Regulatory Action

This information and request was included in the 74-day letter sent on December 10, 2010.

References

1. 

2.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROSS W FILICE
12/10/2010
CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement

NDA/BLA Number: 21064  Applicant: Lantheus  Stamp Date: 09/29/2010
Drug Name: Definity (perflutren)  NDA/BLA Type: sNDA

Major proposed labeling changes

File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908
Reference ID: 2871527
### CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement

**Studies Submitted in Support of Changes** (see appendix for details)

**Efficacy Changes**

Safety Changes

4 trials are submitted in support of the proposed safety changes. 3 of these are from the Postmarketing Requirements that arose after the Advisory Committee meeting in 2008. These include a retrospective database review of critically ill patients who received Definity, a prospective registry of patients in typical clinical practice who received Definity, and a small prospective evaluation of pulmonary hemodynamics in patients with and without pulmonary hypertension.

On initial overview of the NDA/BLA application for filing:

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FORMAT/ORGANIZATION/LEGIBILITY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Identify the general format that has been used for this application, e.g., electronic CTD.</td>
<td>X</td>
<td></td>
<td></td>
<td>eCTD</td>
</tr>
<tr>
<td>2. On its face, is the clinical section organized in a manner to allow substantive review to begin?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Is the clinical section indexed (using a table of contents) and paginated in a manner to allow substantive review to begin?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. For an electronic submission, is it possible to navigate the application in order to allow a substantive review to begin (e.g., are the bookmarks adequate)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Are all documents submitted in English or are English translations provided when necessary?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Is the clinical section legible so that substantive review can begin?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LABELING</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Has the applicant submitted the design of the development package and draft labeling in electronic format consistent with current regulation, divisional, and Center policies?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908

Reference ID: 2871527
## CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SUMMARIES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Has the applicant submitted all the required discipline summaries (i.e., Module 2 summaries)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Has the applicant submitted the integrated summary of safety (ISS)?</td>
<td>X</td>
<td></td>
<td></td>
<td>Summary of Clinical Safety is provided in 2.7.4. ISS section only provides tables in 5.3.5.3.28.</td>
</tr>
<tr>
<td>10. Has the applicant submitted the integrated summary of efficacy (ISE)?</td>
<td>X</td>
<td></td>
<td></td>
<td>Summary of Clinical Efficacy is provided in 2.7.3. ISE section only provides tables in 5.3.5.3.27.</td>
</tr>
<tr>
<td>11. Has the applicant submitted a benefit-risk analysis for the product?</td>
<td>X</td>
<td></td>
<td></td>
<td>2.5.6 Benefits and Risks Conclusion</td>
</tr>
<tr>
<td>12. Indicate if the Application is a 505(b)(1) or a 505(b)(2). If Application is a 505(b)(2) and if appropriate, what is the reference drug?</td>
<td>X</td>
<td></td>
<td></td>
<td>505(b)(2) - sNDA</td>
</tr>
<tr>
<td><strong>DOSE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. If needed, has the applicant made an appropriate attempt to determine the correct dosage and schedule for this product (i.e., appropriately designed dose-ranging studies)?</td>
<td>X</td>
<td></td>
<td></td>
<td>Proposed dosing scheme is unchanged</td>
</tr>
<tr>
<td>Study Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample Size:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location in submission:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arms:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EFFICACY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Do there appear to be the requisite number of adequate and well-controlled studies in the application?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pivotal Study #1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMP 115-501: blinded read of rest and stress images from 5 prior sponsor trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pivotal Study #2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMP 115-502: efficacy literature review</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Do all pivotal efficacy studies appear to be adequate and well-controlled within current divisional policies (or to the extent agreed to previously with the applicant by the Division) for approvability of this product based on proposed draft labeling?</td>
<td>X</td>
<td></td>
<td></td>
<td>Incomplete subgroup analysis. DMP 115-418: age, gender, race</td>
</tr>
<tr>
<td>16. Do the endpoints in the pivotal studies conform to previous Agency commitments/agreements? Indicate if there were not previous Agency agreements regarding primary/secondary endpoints.</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. Has the application submitted a rationale for assuming the applicability of foreign data to U.S. population/practice of medicine in the submission?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SAFETY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Has the applicant presented the safety data in a manner consistent with Center guidelines and/or in a manner previously requested by the Division?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908

Reference ID: 2871527
### CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>19. Has the applicant submitted adequate information to assess the arrhythmogenic potential of the product (<em>e.g.</em>, QT interval studies, if needed)?</td>
<td>X</td>
<td></td>
<td></td>
<td>(b) (4) presents QT interval analysis.</td>
</tr>
<tr>
<td>20. Has the applicant presented a safety assessment based on all current worldwide knowledge regarding this product?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21. For chronically administered drugs, have an adequate number of patients (based on ICH guidelines for exposure(^1)) been exposed at the dose (or dose range) believed to be efficacious?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22. For drugs not chronically administered (intermittent or short course), have the requisite number of patients been exposed as requested by the Division?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23. Has the applicant submitted the coding dictionary(^2) used for mapping investigator verbatim terms to preferred terms?</td>
<td>X</td>
<td></td>
<td>MedDRA</td>
<td></td>
</tr>
<tr>
<td>24. Has the applicant adequately evaluated the safety issues that are known to occur with the drugs in the class to which the new drug belongs?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25. Have narrative summaries been submitted for all deaths and adverse dropouts (and serious adverse events if requested by the Division)?</td>
<td>X</td>
<td></td>
<td></td>
<td>(b) (4) individual study protocols exist, but reports are not provided, thus no narrative summaries provided for these individual trials.</td>
</tr>
</tbody>
</table>

### OTHER STUDIES

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>26. Has the applicant submitted all special studies/data requested by the Division during pre-submission discussions?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27. For Rx-to-OTC switch and direct-to-OTC applications, are the necessary consumer behavioral studies included (<em>e.g.</em>, label comprehension, self selection and/or actual use)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PEDIATRIC USE

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>28. Has the applicant submitted the pediatric assessment, or provided documentation for a waiver and/or deferral?</td>
<td>X</td>
<td></td>
<td></td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

### ABUSE LIABILITY

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>29. If relevant, has the applicant submitted information to assess the abuse liability of the product?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### FOREIGN STUDIES

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>30. Has the applicant submitted a rationale for assuming the applicability of foreign data in the submission to the U.S. population?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### DATASETS

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. Has the applicant submitted datasets in a format to allow</td>
<td>X</td>
<td></td>
<td></td>
<td>(b) (4) Datasets:</td>
</tr>
</tbody>
</table>

---

\(^1\) For chronically administered drugs, the ICH guidelines recommend 1500 patients overall, 300-600 patients for six months, and 100 patients for one year. These exposures MUST occur at the dose or dose range believed to be efficacious.

\(^2\) The “coding dictionary” consists of a list of all investigator verbatim terms and the preferred terms to which they were mapped. It is most helpful if this comes in as a SAS transport file so that it can be sorted as needed; however, if it is submitted as a PDF document, it should be submitted in both directions (verbatim -> preferred and preferred -> verbatim).

File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908

Reference ID: 2871527
IS THE CLINICAL SECTION OF THE APPLICATION FILEABLE? Yes

If the Application is not fileable from the clinical perspective, state the reasons and provide comments to be sent to the Applicant.

Please identify and list any potential review issues to be forwarded to the Applicant for the 74-day letter.

1. Provide complete study reports including demographics, narrative results, tabular results, and complete datasets for each of [redacted]. Also provide complete safety data and analysis including narrative summaries of any deaths, serious adverse events, or dropouts. These trials are:

2. Provide subgroup analysis of efficacy and safety by age, gender, and racial subgroups for all trials except literature reviews [21 CFR 314.50(d)(v)]. This has already been done for DMP 115-418, but otherwise appears incomplete or absent in the remaining trials. Please provide this analysis, or justification for exclusion, for the following trials:
d. DMP 115-416

e. DMP 115-415

f. (b)(4)

and for the following (b)(4)

3. Provide a signed statement of Good Clinical Practice that states that all clinical studies were performed under the supervision of an IRB and with adequate informed consent procedures.

Ross Filice, M.D. 11/17/2010
Reviewing Medical Officer Date

Louis Marzella, M.D. 11/17/2010
Clinical Team Leader Date

Appendix - Submitted Clinical Trials

File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908
Safety Changes

1. **DMP 115-416**
   - prospective open-label trial - 16 pts with pulmonary hypertension (PASP > 35 mmHg), 16 controls
   - primary endpoint: pulmonary artery hemodynamics (many parameters)
   - secondary endpoint: SAE, AE, immunology parameters, labs, vital signs, physical exams, ECGs
   - no prospective statistical evaluation defined, post-hoc comparisons were 2-sided, 5% error, Wilcoxon Rank sum test
   - Conclusion: no statistically or clinically significant changes in parameters

2. **DMP 115-415**
   - prospective open-label surveillance registry for safety, Feb 2008-Apr 2009
   - population: 1053 patients with suboptimal echocardiograms, regular clinical practice, not critically ill, some rest some stress
   - primary endpoint: death or life-threatening events within 30 minutes of Definity
   - secondary endpoint: SAE and AE up to 24 hrs after Definity, monitoring parameters (vital signs, ECG, oxygen sat) up to 30 minutes after Definity
   - 10.8% treatment emergent AE (4.5% rest, 13% stress)
   - 13% AE at rest, 27.7% AE stress
   - no deaths or SAE

3. **DMP 115-418**
   - retrospective database review of 1000 patients with propensity score matching
   - primary endpoint: 48 hour mortality
   - secondary endpoint: all cause in-hospital mortality, acuity of illness and prior risk of mortality, subgroup analysis of 48 hour mortality
   - Conclusion: mortality benefit in Definity group (2.14% death in Definity, 3.09% death in non-contrast, OR: 0.686 [0.596-0.789])
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROSS W FILICE
12/02/2010

LIBERO L MARZELLA
12/03/2010
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MICHELE B FEDOWITZ
11/23/2010

LIBERO L MARZELLA
11/23/2010

Reference ID: 2868360